Advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression.
VIEW PRODUCT PIPELINEAbout
We are a neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing innovative therapeutics to improve the lives of people living with neurological and psychiatric disorders.
Read MoreLatest News
Xenon to Report Q3 2024 Financial Results on November 12, 2024
Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference
Xenon Showcases Azetukalner Data at 15th European Epilepsy Congress
Xenon Expands Leadership Team with Matthew D. Ronsheim, Ph.D. as Chief Operating Officer
All News
Investors
Visit our Investor page for News Releases, Annual & Quarterly Reports, Webcasts & Events
View Investor Area
